Active	Status	Sponsor type	Region	Phase	Filter
9 Active 4 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ellis, Jessica
KEYNOTE B84, NCT04815720: Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck P1b data in combination with pepinemab for recurrent or metastatic HNSCC Apr 2022 - Apr 2022: P1b data in combination with pepinemab for recurrent or metastatic HNSCC	Completed	1/2	49	US	pepinemab + pembrolizumab, KEYTRUDA®	Vaccinex Inc., Merck Sharp & Dohme LLC	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)	07/24	07/24
PIKture-01, NCT06239467: First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer	Recruiting	1	150	Europe, US, RoW	OKI-219, Fulvestrant, Trastuzumab	OnKure, Inc.	Advanced Cancer, Breast Cancer	06/26	08/27